Development and Validation of a Symptom-Based Patient-Reported Outcome Measure for MASH: The CLDQ-MASH Symptom Questionnaire
- 31 July 2026
- journal article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Abstract
INTRODUCTION: Metabolic dysfunction-associated steatohepatitis (MASH) is associated with a substantial symptom burden. However, no validated symptom-focused patient-reported outcome instrument exists for this population. We aimed to develop and validate the MASH Symptom Questionnaire. METHODS: We analyzed subjects with metabolic dysfunction-associated steatotic liver disease (MASLD) from the global MASLD registry with clinical data and completed Chronic Liver Disease Questionnaire-MASH (CLDQ-MASH) instruments. For the new instrument development and preliminary validation, we used CLDQ-MASH items supplemented with symptom-related items from other generic instruments (development sample: n = 2,066) and expert input. A list of 50 symptom-related items was identified. After removal of redundancy, 36 items were retained and evaluated using exploratory factor analysis. Standard pipeline for validation of a patient-reported outcome instrument was applied. The instrument was validated using another independent validation sample from global MASLD registry (validation sample: n = 2,541). RESULTS: In the development phase, 36 items were distributed in 8 symptom domains: mental, cognitive, fatigue, systemic, abdominal, health distress, sleep disturbance, and peripheral symptoms domains. Seven of 8 domains demonstrated a Cronbach alpha >0.80 (high internal consistency); the remaining peripheral symptoms domain included diverse items. The domain scores significantly discriminated across histologic disease severity (early fibrosis vs. F2-F3 vs. cirrhosis), liver stiffness categories (20 kPa) in both development and independent validation samples. The instrument discriminated well based on nonhepatic comorbidities (type 2 diabetes, hypertension, psychiatric, sleep, pruritus, clinically overt fatigue, GERD, other GI disorders). Similar strong validation properties were noted in the independent validation sample. DISCUSSION: The 36-item, 8-domain CLDQ-MASH Symptom Questionnaire represents the first validated, disease-specific symptom questionnaire for patients with MASH showing good psychometric properties. With further external validation, the CLDQ-MASH Symptom Questionnaire has the potential to serve as a standardized tool in both clinical research and routine practice to comprehensively assess disease burden and treatment response.Keywords
This publication has 25 references indexed in Scilit:
- Self-Reported Cognitive Function in Metabolic Dysfunction–associated Steatotic Liver Disease and Metabolic Dysfunction–associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom TrialsJournal of Clinical and Experimental Hepatology, 2026
- Validation of the Chronic Liver Disease Questionnaire for MASH (CLDQ-MASH)JHEP Reports, 2024
- The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver diseaseJHEP Reports, 2024
- Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK StudyClinical Gastroenterology and Hepatology, 2023
- Clinical and Patient-Reported Outcomes From Patients With Nonalcoholic Fatty Liver Disease Across the World: Data From the Global Non-Alcoholic Steatohepatitis (NASH)/ Non-Alcoholic Fatty Liver Disease (NAFLD) RegistryClinical Gastroenterology and Hepatology, 2022
- Validation of Chronic Liver Disease Questionnaire for Nonalcoholic Steatohepatitis in Patients With Biopsy-Proven Nonalcoholic SteatohepatitisClinical Gastroenterology and Hepatology, 2019
- Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016–2030Journal of Hepatology, 2018
- Patient-Reported Outcomes for Patients With Chronic Liver DiseaseClinical Gastroenterology and Hepatology, 2018
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015